|
|
Vaccine Detail
|
Autologous monocyte-derived mature DCs pulsed with p53, survivin and telomerase-derived peptides |
| Vaccine Information |
- Vaccine Name: Autologous monocyte-derived mature DCs pulsed with p53, survivin and telomerase-derived peptides
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007580
- Type: Dendritic cell
- Status: Research
- Preparation: Autologous monocyte-derived mature dendritic cells (DC) pulsed with p53, survivin and telomerase-derived peptides (HLA-A2+ patients) (Trepiakas et al., 2010).
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: A significant lower blood level of regulatory T cells (CD25(high) CD4 T cells) was demonstrable after six vaccinations in patients with stable disease compared with progressive disease (Trepiakas et al., 2010).
|
| References |
Trepiakas et al., 2010: Trepiakas R, Berntsen A, Hadrup SR, Bjørn J, Geertsen PF, Straten PT, Andersen MH, Pedersen AE, Soleimani A, Lorentzen T, Johansen JS, Svane IM. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy. 2010; 12(6); 721-734. [PubMed: 20429791].
|
|
